0.55
0.55 (0%)
As of Feb 11, 2025
Marinus Pharmaceuticals, Inc. [MRNS]
Source:
Company Overview
Marinus Pharmaceuticals, Inc. is a commercial-stage pharmaceutical company dedicated to the development of innovative therapeutics for the treatment of seizure disorders, including rare genetic epilepsies and status epilepticus, which includes the use of ZTALMY.
| Country | United States |
| Headquarters | radnor, pennsylvania |
| Phone Number | (484) 801-4670 |
| Industry | manufacturing |
| CEO | Scott Braunstein, M.D. |
| Website | www.marinuspharma.com |
Financial Year:
Financial Overview (Dollars in Millions)
| Revenue | $8.5 |
| Operating Profit | $-21.1 |
| Net Income | $-24.2 |
| Net Cash | $-78.4 |
Profit Ratios
| Gross Margin | $8.5 |
| Operating Margin | -246.8 |
| Profit as % of Revenues | -35.3% |
| Profit as % of Assets | -20.7% |
| Profit as % of Stockholder Equity | 36.3% |
Management Effectiveness
| Return on Equity | 36.3% |
| Return on Assets | -38.1% |
| Turnover Ratio | 7.3% |
| EBITA | $-21.1 |
Balance Sheet and Cash Flow Measures
| Total Assets | $63.6 |
| Total Liabilities | $130.4 |
| Operating Cash Flow | $-87.8 |
| Investing Cash Flow | $28.7 |
| Financing Cash Flow | $-19.4 |
